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Maf1, first identified in yeast 
Saccharomyces cerevisiae, is general negative 
regulator of RNA polymerase III (Pol III). 
Transcription regulation by Maf1 is 
important under stress conditions and during 
the switch between fermentation and 
respiration. Maf1 is composed of two domains 
conserved during evolution. We report here 
that these two domains of human Maf1 are 
resistant to mild proteolysis and interact 
together as shown by pull-down and size 
exclusion chromatography and that the 
comparable domains of yeast Maf1 interact in 
a two-hybrid assay. Additionally, in yeast, a 
mutation in the N-terminal domain is 
compensated by mutations in the C-terminal 
domain. Integrity of both domains and their 
direct interaction is necessary for Maf1 
dephosphorylation and subsequent inhibition 
of RNA polymerase III transcription on a 
nonfermentable carbon source. These data are 
the  report relating Maf1 structure to RNA 
polymerase III transcription inhibition. 
 
In eukaryotic cells, RNA polymerases (Pol) I 
and III are responsible for the synthesis of RNA 
species involved in ribosome biogenesis and the 
translation process. RNA synthesis by Pol I and 
Pol III represents more than 80% of all yeast 
nuclear transcription activity and is controlled in 
a coordinated way in response to various cellular 
and environmental conditions (1, 2, 3). 
Pol III is responsible for the transcription of 
~300 different genes in yeast (class III genes), 
mostly tRNA genes (4, 5, 6). Analyses of the 
Pol III transcription system in yeast have 
revealed a series of protein-DNA and 
protein-protein interactions leading to the 
recruitment of Pol III to its target tRNA genes: 
binding of the six-subunit TFIIIC factor to the 
intragenic promoter, TFIIIC-directed recruitment 
and assembly of the three components of TFIIIB 
(TBP, Brf1 and Bdp1), and subsequent 
recruitment of the seventeen-subunit Pol III 
enzyme (7). Whereas the essential factors and the 
basal mechanisms of class III gene transcription 
are well defined, much less is known about the 
molecular mechanisms of Pol III regulation. 
The unique global negative regulator of Pol 
III transcription in yeast is the Maf1 protein that 
mediates several signaling pathways, but is not 
essential (8, 9). In addition to the down-
regulation that normally occurs in the stationary 
phase and in response to various drugs, also 
DNA damage, oxidative stress, secretory defects 
and respiratory growth require Maf1 to achieve 
Pol III repression (8, 10, 11, 12). The activity of 
Maf1 is regulated by its phosphorylation, which 
occurs in favorable conditions. Apart from 
decreasing direct Maf1 binding to Pol III (13), 
this phosphorylation acts both to relocate the 
nuclear pool of Maf1 to the cytoplasm (14) and 
to prevent import of cytoplasmic Maf1 to the 
nucleus (15). Diverse unfavorable conditions 
lead to rapid Maf1 dephosphorylation and its 
nuclear accumulation, physical association of the 
dephosphorylated Maf1 with Pol III, and 
genome-wide Maf1 targeting to PoI III- 
transcribed genes (13, 16).  
The Pol III machinery is remarkably 
conserved between yeast and human. The most 
conserved components are those involved in 
transcription complex assembly: the 131 
subunit of TFIIIC and two components of TFIIIB 
(TBP, Brf1). The five Pol III-specific subunits in 
yeast (C31, C34, C37, C53 and C82), all have 
structural and functional homologs in human 
cells (17). Also Maf1 is conserved across 
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eukaryotic organisms from yeast to man (9). This 
conservation is of particular interest considering 
that misregulation of Pol III in human has been 
linked to malignant transformation. Excessive 
activation of Pol III-directed transcription can 
lead to tumorgenesis (18, 19, 20, 21) and, in line 
with this observation, two mammalian tumor 
suppressors, Rb and p53, have been shown to act 
as global repressors of Pol III transcription (22). 
Recent results of several groups report Maf1-
mediated repression of Pol III transcription in 
human implicating HsMaf1 ortholog as a new 
class of mammalian Pol III regulators (23, 24, 
25, 26). The involvement of HsMaf1 in the 
aberrant control of Pol III transcription in cancer 
cells remains to be studied. In the light of the 
high evolutionary conservation of the Pol III 
machinery including Maf1, insights into Pol III 
(mis)regulation by Maf1 gained by studying 
model organisms, such as yeast, should provide 
some insight into the role of HsMaf1 in cancer.  
Our current interest concerns the relation 
between Maf1 structure and activity. All 
members of the Maf1 family have three fairly 
conserved segments (9) which, however, show 
no significant homology with protein domains of 
known function resulting in the striking lack of 
information on the functional significance of 
those regions. Point mutations have only 
highlighted the importance of several serine 
residues (mostly not phylogenetically conserved) 
and two nuclear localization sequences (15, 16, 
27). We describe here identification of two 
conserved domains in HsMaf1 and show that the 
corresponding regions in yeast Maf1 interact. 
This interaction is crucial for the regulation of 
Maf1 activity by phosphorylation. Our data 
provide the first insight into the Maf1 structure in 
relation to Pol III regulation. 
 
Experimental Procedures 
 
Expression and purification of HsMaf1 
protein - Human full-length Maf1 (HsMaf1)(aa 
1-256) was expressed as a C-terminal 6His-
tagged protein (HsMaf1-CHis) in insect cells. 
The protein was purified using cobalt affinity 
resin (Clontech). As a final purification step, the 
protein was applied to size-exclusion 
chromatography equilibrated in buffer I (10 mM 
Tris, pH 7.4, 150 mM NaCl, 1 mM DTT).  
HsMaf1 fragments aa 1-45, aa 1-59, aa 1-63, 
aa 1-74 and aa 85-210 were co-expressed for 15 
h at 18ºC in E. coli BL21 Gold (DE3) cells 
(Stratagene) using expression vector pETMCN-
His (C. Romier, IGBMC) coding for TEV-
cleavable N-terminal His-tagged HsMaf1 aa 1-
45, aa 1-59, aa 1-63, aa 1-74 and expression 
vector pETMCN (as above) coding for non-
tagged Maf1 aa 85-210. The complex was 
purified by Ni-affinity chromatography (NiNTA, 
Qiagen) followed by TEV protease cleavage and 
a second Ni-affinity chromatography to remove 
the His-Tag. The complex was further purified 
by anion-exchange chromatography (MonoQ 
10/100, GE Healthcare) and size exclusion 
chromatography. 
HsMaf1 fragment aa 82-236 was expressed 
from pETM11 (EMBL) as a potentially TEV-
cleavable, N-terminal His-tagged protein which 
was purified by nickel affinity chromatography 
(Chelating Sepharose, GE Healthcare). However 
the purified tagged protein HsMaf1 82-236 aa 
could not be cleaved by TEV protease - most 
likely due to its aggregated state. The tagged 
protein was further purified by anion-exchange 
chromatography (5 ml HiTrap Q-Sepharose HP, 
GE Healthcare) and size-exclusion 
chromatography (S200 10/300, GE Healthcare). 
Limited proteolysis of HsMaf1 protein - 
hMaf1-CHis protein at a concentration of 
1 mg/ml was digested with trypsin for 30 min. at 
4ºC in buffer I using a protease:protein ratio of 
1:150 (w:w). The reaction was stopped by adding 
PMSF to a final concentration of 1 mM. The 
proteolysis product was concentrated to 2 mg/ml 
using an Amicon MWCO 3000 concentrator 
(Millipore) and subsequently purified using two, 
consecutive Superdex 200 10/300 columns (GE 
Healthcare) to improve resolution in buffer I. 
Purified HsMaf1 fragments were unambiguously 
identified using a combination of Edman 
degradation and Mass Spec (Q-Tof). 
Yeast S. cerevisiae strains and media - The 
yeast strains used in this study included wild type 
YPH500 (MAT, ade2-101, his3-200, leu2-1, 
lys2-801, trp1-63, ura3-52), maf1-, a 
derivative of YPH500 (13) and the two-hybrid 
reporter strain Y190 (MATa, gal4–542, gal80–
538, his3, trp1–901, ade2–101, ura3–52, leu2–3, 
112, URA3::GAL1-lacZ, LYS2::GAL1(UAS):: 
HIS3, cyh
R
) (28). Rich media contained 1% yeast 
extract, 2% peptone and 2% glucose (YPD) or 
2% glycerol (YPGly). The minimal medium 
(SC) contained 2% glucose and 0.67% yeast 
nitrogen base without amino acids (29). Solid 
media contained 2% agar. All reagents were 
from Difco.  
Construction of plasmids to express 
fragments of yeast Maf1 protein for two-hybrid 
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study - DNA encoding fragments aa 1-12, 1-16 
and 1-23 of domain A of yeast Maf1 were 
synthesized as oligonucleotides. The larger DNA 
sequences, encoding aa 1-34, 1-39 and 1-42 
fragments were amplified using forward primer 
5’TCATCGGGATCCGAATGAAATTTATTGA
TGAGCTAGATATAGAGAGAGTG3’ and 
reverse primers: 5’TCATCGCTCGAGTTTTCT 
ATCTGATGCAACCGC3’, 5’TCATCGCTCGA 
GTGATGCAACCGCCTTTGTTGTG3’ and 5’T 
CATCGCTCGAGTGTTGTGAAAATATCGCA
ACTGCC3’, respectively. The intron sequence 
of the MAF1 gene (localized between bp 7 and 
87) was excluded. DNA encoding fragment aa 
196-349 fragment of BC domain was amplified 
with primers: 5’TCATCGGGATCCGATCTGG 
TACAGCAACCAACAATG3’ and 5’TCATCG 
CTCGAGTTCGCCTGTACTCGAATTTAG3’.
All MAF1 parts were amplified with BamHI and 
XhoI termini fragments, and inserted into 
MATCHMAKER GAL4 Two-Hybrid Vectors 
(Clontech) – either the pACT2 plasmid carrying 
the activation domain of Gal4 or the pAS2 
plasmid carrying the binding domain of Gal4. 
The resulting plasmids were named pACT2-
Maf1-A(1-12), pACT2-Maf1-A(1-16), pACT2-
Maf1-A(1-23), pACT2-Maf1-A(1-34), pACT2-
Maf1-A(1-39), pACT2-Maf1-A(1-42) and pAS2-
Maf1-BC(196-349). Expression of fusion 
proteins involving HA-tagged truncated versions 
of A domain was verified by Western blotting. 
Each of the derivatives of pACT2 and the single 
derivative of pAS2, were co-expressed pair wise 
in the two-hybrid reporter strain Y190. Cells 
containing these two plasmids were patched on 
SC medium lacking leucine and tryptophan. The 
patches were then examined for β-galactosidase 
activity using an overlay plate assay (30). The 
intensity of the coloration was calibrated by 
comparison with a pair of known interactors 
(95/55, two TFIIIC subunits) for which the β-
galactosidase activity had been measured 
previously (31). For a β-galactosidase liquid 
assay cell lysates were prepared and the activity 
was measured colorimetrically as nmoles of 
ONPG (o-nitrophenyl- β-D-galactopiranoside) 
hydrolyzed per minute per mg of protein. 
Conversion 0.0045 x A420 = 1 nmole ONPG 
cleaved was used (30). 
Generation of yeast S. cerevisiae Maf1 
mutant strains - MAF1 gene was cut from 
pFL44-MAF1 (32) subcloned in pRS315 (LEU2, 
CEN) plasmid (33) resulting in pRS315-MAF1. 
The pAG70, pLM11 and pLM12 plasmids were 
derived from pRS315-MAF1 using a rapid 
method for localized mutagenesis (34). For this 
purpose MAF1 fragment encoding aa 1-180 was 
PCR-amplified from pRS315-MAF1 under 
mutagenic conditions using 
5’CGAGTTGCTTGTCAATCAGG3’ and 
5’CTGCTACTGCTCCTTCTTCT3’ primers and 
Diversify PCR Random Mutagenesis Kit 
(Clontech). The product of the low-fidelity PCR 
was transformed together with gapped linear 
plasmid pRS315-MAF1 (digested with BclI and 
BsgI) into the YPH500 maf1-Δ strain (13). 
Transformants, selected on minimal medium 
lacking leucine, were subsequently tested for 
Maf1 activity by replica-plating on YPGly and 
incubation at 37ºC for three days; Among 38 
independent mutants, pAG70 (maf1-K35E) was 
selected from colonies that showed defective 
growth. To isolate pML11 (maf1-K35E-D250E) 
and pML12 (maf1-K35E-V260D-N344I) 
plasmids carrying suppressor mutations, pRS315 
plasmid pAG70 (carrying the previously isolated 
maf1 allele with the K35E mutation) was 
digested with BsaBI and Bsu36I and introduced 
into the YPH500 maf1-Δ strain together with a 
MAF1 fragment encoding BC domain (aa 174-
375) PCR-amplified under mutagenic conditions 
using primers: 5’AGAAGAAGGAGCAGTAG 
CAG3’ and 5’CGTATTCTCCTTCGTATTCA 
3’. The obtained library of potential suppressor 
mutants was screened for overcoming the 
thermosensitivity on YPGly medium caused by 
the K35E mutation. This screen resulted in 
identification of pLM11 and pLM12 suppressor 
mutations in BC domain of Maf1. 
To generate mutations in the two-hybrid 
plasmids carrying fragments encoding Maf1 
domains, the BamHI-XhoI fragment encoding aa 
1-42 of Maf1 in the pACT2-Maf1-A(1-42) 
plasmid was substituted with a PCR-amplified 
fragment of the maf1 allele K35E from pAG70. 
Similarly the mutations found in pML11 and 
pML12 were introduced in pAS2-Maf1-BC(196-
349). The N344I mutation found in the pML12 
plasmid was introduced to pAS2-Maf1-BC(196-
349) by using a modified reverse primer 
3’TCATCGCTCGAGTTCGCCTGTACTCGAA
ATTAGACGCGAGC5’ with a mutation leading 
to the desired amino acid substitution. 
QuickChange Site-Directed Mutagenesis Kit 
(Stratagene) was used to introduce D250E, 
N344I, V260D and V260D-N344I to pRS315-
MAF1. The sequences of primers used are 
available upon request. 
Northern analysis - Cells (50 ml of liquid 
culture, A600 of about 0.8) were harvested by 
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centrifugation and resuspended in 50 mM Na 
acetate, pH 5.3, 10 mM EDTA. Total RNA was 
isolated by heating and freezing the cells in the 
presence of SDS and phenol as described 
previously (12,35). RNA (5 g per sample) was 
resolved by electrophoresis in 10% PAGE with 8 
M urea, transferred to Hybond-N+ membrane 
(Amersham) by electroblotting in 0.5 x TBE and 
crosslinked by UV radiation (1200 mJ/cm
2
). The 
membrane was prehybridized in 7% SDS; 0.5 M 
sodium phosphate pH 7.2; 1 mM EDTA pH 7.0; 
1% BSA and hybridized at 37ºC in the same 
solution with oligonucleotide probes labeled with 
[γ-32P]-ATP and T4 polynucleotide kinase (New 
England Biolabs). The probes were: 5'TATTCC 
CACAGTTAACTGCGG3’ for tRNALeu(CAA), 
5'CCTCCAGATGACTTGACCG3’ for tRNAPhe 
(GAA) and 5'GGATTGCGGACCAAGCTAA3’ 
for U3 snoRNA. After hybridization the blots 
were washed 2 x 10 min. with 1SSC, 1% SDS 
and 3 x 10 min. with 0.5SSC, 0.1% SDS at 
37ºC and exposed to an X-ray film or a 
phosphoimager screen (Molecular Dynamics).  
Protein Extraction and Immunoblotting - To 
avoid action of endogenous kinases or 
phosphatases during cell harvesting and protein 
extraction, yeast cells were rapidly harvested by 
centrifugation at 4°C, and 20% trichloroacetic 
acid (TCA) was added to the cell pellet as 
described earlier (12, 13). Cells were broken 
with acid-washed glass beads, the supernatant 
was retained and TCA-precipitated proteins were 
pelleted by centrifugation. The pellet was 
resuspended in sample buffer (pH 8.8) and boiled 
for 5 min. Protein extracts were separated on 
SDS-PAGE using a modified acrylamide: 
bisacrylamide ratio (33.5:0.3). One lane was 
loaded with protein from 1 OD of cell culture 
(10–20 μg). The membrane was blocked for 30 
min. in TBST (10 mM Tris, 150 mM NaCl, 
0.05% Tween 20) containing 5% fat-free dry 
milk and then incubated for 1 h with Maf1- 
specific antibody at 1:10 000 dilution (12). The 
membrane was incubated with secondary anti-
rabbit antibody coupled to horseradish 
peroxidase (DAKO) which was then visualized 
by chemiluminescence using the ECL detection 
kit (Milipore).  
 
RESULTS 
 
Two domains of Maf1 do interact. The yeast 
MAF1 gene encodes a hydrophilic protein of 395 
amino acids rich in serine and asparagine 
residues, with a predicted molecular mass of 44.7 
kDa. Screening of multiple databases with the 
yeast Maf1 sequence revealed numerous 
orthologs in other eukaryotes: one in human, 50 
in animals, 28 in plants and 27 in lower 
eukaryotes, but none in prokaryotes. Maf1 
proteins contain three phylogenetically 
conserved sequence regions, labeled A, B and C 
(9). The similarity of the yeast and human Maf1 
sequences is presented in figure 1 and more 
Maf1 proteins are aligned in figure S1. Since the 
distance between the B and C segments of 
approximately 10 aa is constant in evolution, 
with the exception of Aspergilus nidulans 
(insertion of 15 aa), we consider this region 
could be a single domain named here as BC. In 
contrast, the space between regions A and B 
largely varies between species. The A and BC 
domains are fused in Encephalitozoon cuniculi 
whereas in the yeast Saccharomyces cerevisiae 
and Candida glabrata they are separated by a 
long linker of 182 aa and 174 aa, respectively. 
Within the BC domain signature sequences for 
the Maf1 protein family can be identified 
(PDYDFS and LWSFnYFFYNKklKR, 
Supplemental Figure S1) (9). These sequence 
"motifs" are not reported in the PROSITE 
database. Interestingly, in the majority of Maf1 
orthologs, the second motif includes a nuclear 
targeting signal, which was proved to be 
functional in S. cerevisiae Maf1 (15).  
To experimentally characterize the structure 
organization of human Maf1 (HsMaf1), we 
carried out limited proteolysis experiments in 
combination with size-exclusion chromatography 
as shown in figure 2. Proteolytically stable 
fragments are considered to be structurally well 
defined, whereas protease-sensitive sites often 
correlate with disordered regions of the proteins. 
Using limited proteolysis with trypsin, HsMaf1 
protein (256 aa) was digested into two major 
stable fragments that were identified as HsMaf1 
aa 1-45 and Maf1 aa 75-234 using a combination 
of N-terminal sequencing and mass spectrometry 
(Q-Tof). The HsMaf1 linker region between 
those fragments (aa 46-74) and the C-terminal 
acidic tail (aa 235-256) were degraded and thus 
presumably unstructured (Figure 2a, lane 2). 
Both fragments were further analyzed by size-
exclusion chromatography. Surprisingly, the two 
HsMaf1 fragments, although of substantially 
different molecular masses, co-eluted in an 
apparent 1:1 stoichiometry, suggesting an 
intramolecular interaction between them (Figure 
2B, red profile).  
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Taking into account the limited proteolysis 
and secondary structure prediction results (data 
not shown), we designed N- and C-terminal 
constructs of HsMaf1 for co-expression in 
bacteria. The N-terminal construct aa 1-45 
corresponds to the minimal domain defined by 
proteolysis while fragment aa 85-210 was 
designed slightly shorter than the initial 
proteolytic fragment. During purification His-tag 
containing recombinant HsMaf1 fragments aa 1-
45 but also slightly larger constructs aa 1-59, aa 
1-63 and aa 1-74  co-precipitate the un-tagged C-
terminal construct aa 85-210 in an apparent 1:1 
stoichiometry suggesting a direct interaction 
between the N- and C-terminal fragments 
(Supplemental Figure S2). 
Analysis by size exclusion chromatography 
supports the results obtained for the proteolytic 
fragments. Constructs aa 1-45 and aa 85-210 co-
elute as a single peak at a volume corresponding 
to the expected molecular weight of ~20 kDa 
(Figure 2B). These results provide further 
support for a direct interaction between A and 
BC domains of HsMaf1. Interestingly, the co-
expressed complex is considerably more 
compact compared to the full-length protein, 
presumably because it is lacking the C-terminal 
acidic tail. In contrast, an additional construct aa 
82-236 that includes the C-terminal acidic tail 
eluted as soluble aggregate (Figure 2, bottom 
panel) when expressed in the absence of the N-
terminal fragment aa 1-45. We also tried to 
express the N-terminal fragment aa 1-45 as GST 
fusion protein, but only obtained minimal 
amounts presumably because the protein 
aggregates after TEV cleavage (data not shown). 
Apparently, N- and C-terminal domains of 
HsMaf1 are both required for the soluble 
expression of HsMaf1 and co-elute during size-
exclusion chromatography indicating a direct 
interaction between them. 
To investigate if the interaction between 
domains of Maf1 is conserved through evolution, 
we analyzed the proposed interaction in yeast, an 
organism more amenable to study structure-
function relationships of Maf1 using the two-
hybrid system. 
The putative BC domain of S. cerevisiae 
Maf1 (aa 196-349) was fused to the DNA-
binding domain of Gal4 and co-expressed with 
various Maf1 A domain constructs fused to the 
Gal4 activation domain in the yeast reporter 
strain Y190. Interactions between fusion proteins 
should result in activation of the β-galactosidase 
reporter gene. Using this approach we observed a 
physical interaction between the BC domain of 
Maf1 encoded by plasmid pAS2-Maf1-BC(196-
349) and fragments of domain A of Maf1 
encoded by plasmids pACT2-Maf1-A(1-42), 
pACT2-Maf1-A(1-39) and pACT2-Maf1-A(1-
34) (Figure 3). Domain BC failed to interact with 
shorter fragments of domain A encoded by 
pACT2-Maf1-A(1-12), pACT2-Maf1-A(1-16) or 
pACT2-Maf1-A(1-23). Cells containing the pair 
pAS2-Maf1-BC and empty pACT2 had no 
detectable -galactosidase activity (data not 
shown in the figure). These results demonstrate 
the specificity of the two-hybrid interaction 
between Maf1 domains and define aa 1-34 as the 
smallest Maf1 A domain still able to bind the BC 
domain. Reciprocal interactions were impossible 
to study because the presence of pAS-Maf1-A 
activates reporter gene in the absence of a 
pACT2 fusion. Importantly pAS2-Maf1-BC was 
also negative tested with pACT2 encoding 
fusions of several genes unrelated to Maf1 and 
encoding components of Pol III complex. 
Taken together, our results as described 
above suggest a strong, direct interaction of the 
A and BC domains of human and yeast Maf1. 
Interaction between A and BC domains is 
important for the function of Maf1. Limited 
proteolysis and two-hybrid results show that the 
A and BC domains of Maf1 together form a 
stable complex, possibly reflecting an active 
conformation of Maf1. To evaluate the 
physiological significance of the interaction 
between the Maf1 domains, we screened for 
mutants impaired in Maf1 function that were 
located in domain A and presumably 
compromised in domain BC binding. MAF1 
fragment encoding aa 1-180 was PCR-amplified 
under mutagenic conditions and transformed into 
maf1-∆ cells together with a gaped single copy 
plasmid encoding Maf1. Transformants were 
selected for poor growth at 37ºC on glycerol 
medium suggesting defect of Maf1 function in 
Pol III repression (12). Sequencing of plasmid 
pAG70 encoding mutant Maf1 isolated in this 
manner revealed mutation K35E located in 
domain A.  
To inspect the effect of K35E mutation in 
Maf1 on Pol III activity, RNA isolated from cells 
grown in the presence of glucose and transferred 
to glycerol medium at 37ºC was analyzed by 
Northern blotting using probes for pre-tRNA
Leu
 
and tRNA
Phe
 (Figure 4A). Following transfer to 
the medium with the nonfermentable carbon 
source, pre-tRNA levels were decreased in the 
wild type but not in maf1-Δ cells (Figure 4A, 
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compare lanes 1, 5 and 6, 10). Similarly to maf1-
, the K35E mutant was defective in its ability to 
repress pre-tRNA transcription upon transfer to 
glycerol medium (Figure 4A, lanes 2 and 7). 
Thus, the single missense mutation within the 
Maf1 A domain precluded Pol III repression in 
maf1-K35E strain. 
One approach to confirm that the K35E 
mutation negatively affects the interaction with 
the BC domain of Maf1 is to identify second-site 
mutations that compensate for the observed 
defects. We looked therefore for second-site 
suppressor mutations within the BC-encoding 
region of MAF1 that allowed maf1 K35E yeast 
cells to grow on glycerol medium at 37ºC. DNA 
encoding aa 174-375 of Maf1 was randomly 
mutagenized by PCR and the mutant pool was 
co-transformed with the pAG70 plasmid 
containing the primary K35E mutation and 
gapped within the region of the BC domain. 
Sequencing of in vivo reconstituted MAF1 from 
six transformants showing reversion of the 
original defect identified two plasmids with 
suppressor mutations: pLM11 (maf1-K35E-
D250E) and pLM12 (maf1-K35E-V260D-
N344I). The remaining transformants were either 
back revertants of K35E mutation or contained 
suppressor mutations outside the MAF1 gene. 
Both isolated suppressors of K35E mutation in A 
domain, single D250E and combined V260D-
N344I, were located in the BC domain, thus 
supporting the interaction between these 
domains.  
Phenotypic characterization of the two 
suppressor strains showed that they compensate 
for the defect of growth on glycerol medium at 
37ºC of the primary K35E mutation (Figure 4B). 
The increased growth capacity of the suppressors 
on glycerol medium was due to a compensation 
of the defect in Pol III regulation observed for 
the K35E mutation. As determined by Northern 
blotting, the suppressor mutations restored the 
ability to repress pre-tRNA transcription upon 
transfer from glucose to glycerol medium (Figure 
4A, lanes 3, 4 and 8, 9). These results indicate 
that the detected genetic interaction between the 
two Maf1 domains is a functional one. 
To further characterize the association of A 
and BC domains, we sought to verify the effects 
of K35E, D250E, V260D and N344I mutations, 
identified in the mutant and suppressor strains, 
on the interaction of Maf1 domains in the two-
hybrid system. The respective mutations were 
generated in the Maf1 A domain fragment fused 
to the Gal4 activation domain in the pACT2-
Maf1-A(1-42) plasmid or the Maf1-BC domain 
fused to the DNA-binding domain of Gal4 in 
pAS2-Maf1-BC(196-349). Various combinations 
of plasmids, one encoding a wild type Maf1 
domain and the other with a mutated domain, 
both fused to the respective Gal domains, were 
co-expressed in the yeast reporter strain followed 
by determination of β-galactosidase activity 
(Figure 5). The K35E mutation of domain A 
reduced the two-hybrid interaction with wild 
type BC domain by ca. 40 % (Figure 5, compare 
lanes 2 and 1). Similarly, both the single D250E 
and the double V260D-N344I mutations in BC 
domain decreased the interaction with wild type 
A domain by 22 and 62 %, respectively (Figure 
5, compare lanes 7 and 8 with lane 1). Moreover, 
the double V260D-N344I mutant showed a 
defect in regulation of tRNA transcription and 
temperature sensitive growth in glycerol medium 
(Supplemental Figure S3). 
Confirming the genetic suppressor results, a 
combination of mutated Maf1 domains restored 
their interaction (Figure 5, compare lanes 3 and 4 
with lane 1). Rather unexpectedly, the strongest 
level of two-hybrid interaction, 80% over the 
wild type one, was observed for the combination 
of K35E domain A and domain BC with a single 
V260D mutation (Figure 5, compare lane 5 with 
lane 1). This indicated that in the double 
suppressor mutation V260D-N344I, identified in 
genetic screen, the former one is in fact sufficient 
to restore the interaction with K35E domain A. 
Domain interaction supports Maf1 
dephosphorylation upon transfer cells to a 
nonfermentable source. As shown before, 
phosphorylation of Maf1 precluded Pol III 
repression when yeast cells were grown on 
glucose medium (14). Transfer of yeast cells to a 
nonfermentable carbon source resulted in Maf1 
dephosphorylation, import of Maf1 into the 
nucleus and inhibition of tRNA synthesis (12). 
Since, we showed that the interaction between 
the Maf1 A and BC domains is crucial for its 
regulatory action on Pol III, we now asked if this 
interaction is also required for efficient 
regulation of Maf1 activity. 
To investigate whether the altered domain 
interactions in the Maf1 mutant proteins were 
correlated with changes in the phosphorylation of 
Maf1, differentially phosphorylated forms of 
Maf1 were resolved by SDS-PAGE and 
identified by immunoblotting at various times 
after culture transfer from glucose to glycerol 
medium (Figure 6). As reported previously, wild 
type Maf1 was quickly dephosphorylated upon 
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this transition. Remarkably, the K35E mutation 
in domain A, preventing its interaction with the 
BC domain, appeared to preclude the 
dephosphorylation of Maf1. Significantly, 
restoring the domain interaction with D250E 
(pLM11) and V260D-N344I (pLM12) 
suppressor mutations re-established rapid 
dephosphorylation of Maf1 following transfer 
from glucose to a nonfermentable carbon source. 
Maf1 dephosphorylation in the suppressor 
mutants was only a little slower than in the wild 
type strain (Suplemental Table S1). Interestingly, 
double V260D-N344I mutation in context of 
wild type A domain precluded interaction 
between domains (Figure 5) and slowed the rate 
of dephosphorylation of Maf1 upon transfer of 
yeast to glycerol medium (Supplemental Figure. 
S4).  
Altogether, these results suggest that the 
interaction of A and BC domain greatly 
facilitates the dephosphorylation of Maf1.  
 
DISCUSSION 
 
In this paper we describe the importance of 
the interaction between two Maf1 domains for its 
activity as a repressor of Pol III transcription.  
Limited proteolysis of HsMaf1 resulted in 
two stable fragments (aa 1-45 and aa 75-234) 
corresponding to the evolutionarily conserved A 
and BC domains. Size-exclusion 
chromatography of the proteolytic fragments 
corresponding to the two domains showed their 
co-elution. Similar fragments were co-expressed 
in bacteria, where they co-purified and co-
migrated during size exclusion chromatography 
as soluble complex. In contrast, both fragments 
behaved poorly when individually expressed. 
Our results suggest that Maf1 A and BC domains 
form modules that do not fold independently but 
rather need to be co-expressed to form a stable 
and soluble entity. In contrast, the connecting 
linker (aa 46-74) and the C-terminal acidic tail 
(aa 235-256) appear solvent exposed and 
unstructured as suggested by HCA analysis 
(Supplemental Figure S6). 
Considering the high conservation of Maf1 
in eukaryotes, the domain interaction and its 
functional role was probed in the model 
organism yeast Saccharomyces cerevisiae. Using 
the yeast two-hybrid system we confirmed the 
physical interaction between A and BC domains 
of Maf1 in yeast and identified the first 34 
residues as the shortest fragment of the A domain 
sufficient for interaction with the BC domain. 
Lack of interaction between further truncated 
fragments of the A domain (aa 1-12, 1-16 or 1-
23) with the BC domain shows the specificity of 
the method used and emphasizes the importance 
of structural features of the A domain for its 
interaction with the BC domain.  
To further investigate the role of domain A 
we isolated single-point mutant K35E (on 
plasmid pAG70). In accordance with its growth 
characteristics, this mutant failed to repress Pol 
III activity. Moreover, as shown by the two-
hybrid system, the K35E mutation reduced the 
interaction between the A and BC Maf1 domains 
by 40%. In support of structural and/or 
functional interactions between the Maf1 
domains, we isolated second-site suppressor 
mutations within the BC domain that 
compensated for the defect caused by the K35E 
mutation in domain A. We found two such 
suppressors: D250E and V260D-N344I. Further 
phenotypic characterization of the suppressor 
strains revealed that these additional mutations in 
BC domain restored not only the ability of the 
K35E-mutated Maf1 to grow on glycerol 
medium at 37ºC, but also its ability to repress  
Pol III activity. Interestingly, residue 260 in 
domain BC seems to be crucial for the 
interaction with domain A. While the V260D 
mutant BC domain interacted with K35E mutant 
domain A over 80% stronger as did wild type 
domain BC, its interaction with the wild type 
domain A was decreased by almost 60% (Figure 
5, lanes 5 and 9). All these results indicated that 
the genetic interaction identified between Maf1 
domains corresponds to a physical interaction 
indispensable for the Maf1 function. 
Bioinformatic analysis using the protein 
structure prediction server (PSIPRED v 2.6) (36, 
37) provides further support for our biochemical 
analysis. In the yeast and human Maf1 A 
domain, two α-helices (aa 7-16 and aa 40-56) 
separated by two adjacent β-strands (aa 24-27 
and 29-35 ) are predicted, while for the BC 
domain five α-helices and concomitant four  
β-strands are predicted (Supplemental Figure 
S5). No secondary structure elements are 
predicted for the linker region. Notably, the 
K35E mutation is located at the end of the 
second β-strand of the A domain. Our attempts to 
minimize the Maf1 A domain identified aa 1-34 
as the smallest fragment still enabling interaction 
with the domains. We hypothesize that the 
interaction between domains A and BC requires 
the first α-helix and two adjacent β-strands. We 
also applied Hydrophobic Cluster Analysis 
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(HCA), a tool to investigate protein stability and 
folding that uses two-dimensional (2D) helical 
representation of protein sequences to identify 
possible hydrophobic cores formed by several 
residues (38). The HCA analysis revealed the 
presence of two regions rich in hydrophobic 
cores corresponding to the A and BC domains of 
S. cerevisiae Maf1 (Supplemental Figure S6). 
Between them a region poor in hydrophobic 
residues was found which, according to the 
alignment of Maf1 eukaryotic sequences, 
corresponds to the linker region between the A 
and BC domains. Similar analysis in human 
Maf1 revealed the same organization of two 
clusters of hydrophobic cores separated by a 
short region free of hydrophobic clusters 
consistent with our limited proteolysis results.  
We found the interaction between the A and 
BC domains, facilitating Maf1 
dephosphorylation, to be necessary for the full 
repression of Pol III activity. One might 
hypothesize that in the same time the interaction 
between domains of Maf1 is influenced by its 
phosphorylation state. Accordingly, different 
forms of Maf1 observed on polyacrylamide gels, 
interpreted as phosphorylated and subsequently 
dephosphorylated form of Maf1, might represent 
different conformational states depending on the 
interaction between A and BC domains. Note 
that the S90A, S101A and S177A, S178A 
mutations in the linker were found to change the 
proportion between slow- and fast-migrating 
Maf1 forms in favor of the former, without 
strongly affecting the phosphorylation status of 
Maf1 thus indicating that residues in the linker 
could strongly modify the Maf1 shape (39).  
Considering that Maf1 contains two 
conserved domains, we propose the unstructured 
linker to become phosphorylated and thus 
modulating the conformational state of Maf1. To 
further investigate this question we used the 
NetPhos 2.0 server (40) to predict possible 
phosphorylation sites in four Maf1 orthologs 
containing linkers of different lengths. Predicted 
phosphorylation sites are frequently found in the 
long linkers between the Maf1 A and BC 
domains of S. cerevisiae and C. glabrata 
relatively, while they are more uniformly 
distributed along the Maf1 sequences of  
C. elegans and H. sapiens, although they are also 
present in their shorter linkers, (Supplemental 
Figure S7). We therefore speculate that 
phosphorylation and dephosphorylation of the 
exposed linker evokes a specific conformation of 
the protein that changes the distance between 
domains modulating their interaction and Pol III 
repression (Supplemental Figure S8). The 
interaction of the domains, mediated by 
dephosphorylation of the linker may affect both, 
the import of Maf1 into the nucleus and its 
interaction with Pol III. This conjecture is 
supported by data of (15) showing that PKA-
mediated phosphorylation of six residues located 
in linker inhibited nuclear import of Maf1 and 
Pol III repression. 
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FIGURE LEGENDS 
 
Fig. 1. Similarity of S. cerevisiae (Sc) and H. sapiens (Hs) Maf1 sequences. Alignment of 
conserved A and BC domains. A and BC domains are boxed and conserved amino acids are 
highlighted. Stars indicate position of K35E, D250E and V260D mutations. 
 
Fig. 2. Domain structure of human Maf1. A. Limited Proteolysis and resulting proteolytic 
fragments of HsMaf1. PAGE of full-length human HsMaf1 protein (1, black) that is digested into two 
stable fragments aa 1-45 and aa 75-234 using trypsin (2, red). Bacterially co-expressed and co-purified 
HsMaf1 domains aa 1-45 and aa 85-210 (4, green). HsMaf1 aa 82-236 (3, blue) lacking the N-terminal 
45 residues was expressed as a control. B. Size-exclusion chromatography profiles. Samples presented 
in (A) were separated on single or tandem Superdex 200 10/300 size-exclusion columns (GE 
Healthcare). Only HsMaf1 construct 82-236 eluates in the void volume of the Superdex 200 size-
exclusion column, while all other samples are monodisperse and elute approximately at volumes 
corresponding to monomers. The elution profile of different molecular weight standards is shown as a 
dashed line. Peaks I, II, III and IV correspond to ovalbumin (Mr=44000), carbonic-anhydrase 
(Mr=29000), ribonuclease A (Mr=13700) and aprotinin (Mr=6500), respectively. Fractions 
corresponding to the red and green elution profiles were analyzed by denaturing gel electrophoresis 
and shown as insets. Fragment 1-45 co-elutes with proteolytic fragments 75-234 and 75-262 (red 
profile) and with the recombinant fragment 85-210 (green profile). 
 
Fig. 3. Two-hybrid interaction of Maf1 domains. pACT2-Maf1-A(1-12), pACT2-Maf1-A(1-16), 
pACT2-Maf1-A(1-23), pACT2-Maf1-A(1-34), pACT2-Maf1-A(1-39) and pACT2-Maf1-A(1-42) 
plasmids were transformed individually together with pAS2 (control plasmid) or pAS2-Maf1- 
BC(196-349) plasmids into yeast strain Y190. Transformants were assayed for β-galactosidase 
expression using overlay plate assay. 
 
Fig. 4. Regulation of Pol III transcription and growth is impaired by the K35E mutation in region 
encoding A domain and restored by second-site suppressor mutations in BC domain of MAF1. maf1-, 
maf1-K35E, maf1-K35E-D250E and maf1-K35E-V260D-N344I mutants and isogenic wild type strain 
YPH500 (WT) were used. A. Cells were grown to exponential phase in glucose medium (YPD) at 
30ºC, then transferred to glycerol medium (YPGly) and incubated at 37ºC for 1.5 h. Total RNA 
isolated from cells was tested by Northern blotting with pre-tRNA
Leu
 and tRNA
Phe
 probes. B. Ten-fold 
serial dilutions of cells grown to exponential phase in glucose medium were plated on glucose medium 
(YPD) and incubated at 30ºC or on glycerol medium (YPGly) and incubated at 37ºC for 2-3 days. 
 
Fig. 5. Two-hybrid interaction of Maf1 domains is impaired by primary mutations in these 
domains and restored by second-site suppressor mutations. A. pACT2-Maf1-A(1-42) plasmid and its 
mutated version were transformed individually with pAS2-Maf1- BC(196-349) plasmid or its mutated 
versions in yeast strain Y190. Transformants were assayed for β-galactosidase expression. Presented 
profile compares following two-hybrid interactions: wild type A and BC domains of Maf1 (1), 
mutated A domain K35E with wild type BC domain (2); mutated A domain K35E with four versions 
of mutated BC domain: D250E (3), V260D-N344I (4), V260D (5), N344I (6), and wild type A domain 
with mutated BC domain containing single D250E, V260D or N344I and double N344I-V260D 
mutations (7-10). B. Scheme of Maf1 domain interaction. 
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Fig. 6. Mutations altering interaction of Maf1 domains affect kinetics of Maf1 dephosphorylation 
upon transfer of yeast from glucose to medium with nonfermentable carbon source. maf1-K35E, maf1-
K35E-D250E and maf1-K35E-V260D-N344I mutant strains and isogenic wild type strain YPH500 
(WT) were grown to exponential phase in YPD glucose medium (Exp), then transferred to glycerol 
YPGly medium, incubated at 37ºC and harvested as indicated. Protein extracts of lysed cells were 
analyzed by Western blotting with polyclonal anti-Maf1 antibodies.  
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